Locus Cell Co., Ltd. (TPEX:6891)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
27.90
+0.05 (0.18%)
Feb 4, 2026, 9:37 AM CST
41.27%
Market Cap5.57B +35.5%
Revenue (ttm)5.18M +397.7%
Net Income-164.24M
EPS-0.83
Shares Out200.00M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume18,300
Average Volume96,564
Open27.85
Previous Close27.85
Day's Range27.65 - 27.95
52-Week Range19.60 - 36.60
Beta0.61
RSI46.58
Earnings DateApr 16, 2026

About Locus Cell

Locus Cell Co., Ltd. focuses on contract development and manufacturing organization (CDMO) services for cell products in Taiwan and internationally. It offers tissue engineering CDMO services for adipose-derived stem cells, nerve cells, chondrocytes, fibroblasts, epithelial cells, 3D printing cell products, and other cell products; and regenerative medical product CDMO services, such as CAR-T, CAR-NK, iPSC, MSC/ADSC, and other cell types. The company is based in New Taipei City, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Yu-Hsiang Chang
Employees 53
Stock Exchange Taipei Exchange
Ticker Symbol 6891
Full Company Profile

Financial Performance

In 2024, Locus Cell's revenue was 2.36 million, an increase of 480.30% compared to the previous year's 406,000. Losses were -113.02 million, 16.6% more than in 2023.

Financial Statements